Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Capital Expenditures (2023 - 2025)

Kura Oncology (KURA) has disclosed Capital Expenditures for 3 consecutive years, with $4.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Capital Expenditures rose 1139.52% to $4.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $6.6 million, a 1306.36% increase, with the full-year FY2025 number at $6.6 million, up 1306.36% from a year prior.
  • Capital Expenditures was $4.6 million for Q4 2025 at Kura Oncology, up from $277000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $4.6 million in Q4 2025 to a low of $16000.0 in Q4 2023.
  • A 3-year average of $661636.4 and a median of $96000.0 in 2023 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: plummeted 83.33% in 2024, then soared 9012.5% in 2025.
  • Kura Oncology's Capital Expenditures stood at $16000.0 in 2023, then surged by 2225.0% to $372000.0 in 2024, then surged by 1139.52% to $4.6 million in 2025.
  • Per Business Quant, the three most recent readings for KURA's Capital Expenditures are $4.6 million (Q4 2025), $277000.0 (Q3 2025), and $1.5 million (Q2 2025).